Joseph S. Ross
#121,156
Most Influential Person Now
Researcher
Joseph S. Ross's AcademicInfluence.com Rankings
Joseph S. Rossengineering Degrees
Engineering
#3824
World Rank
#4952
Historical Rank
Electrical Engineering
#909
World Rank
#983
Historical Rank
Joseph S. Rosscomputer-science Degrees
Computer Science
#4901
World Rank
#5176
Historical Rank
Computational Linguistics
#567
World Rank
#578
Historical Rank
Machine Learning
#1110
World Rank
#1129
Historical Rank
Artificial Intelligence
#1340
World Rank
#1367
Historical Rank
Download Badge
Engineering Computer Science
Joseph S. Ross's Degrees
- PhD Computer Science Stanford University
Similar Degrees You Can Earn
Why Is Joseph S. Ross Influential?
(Suggest an Edit or Addition)Joseph S. Ross's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Exposure to low-dose ionizing radiation from medical imaging procedures. (2009) (1283)
- Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. (2013) (927)
- Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. (2010) (661)
- An Administrative Claims Measure Suitable for Profiling Hospital Performance on the Basis of 30-Day All-Cause Readmission Rates Among Patients With Heart Failure (2008) (517)
- Recent National Trends in Readmission Rates After Heart Failure Hospitalization (2010) (455)
- Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. (2008) (440)
- Trial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis (2009) (369)
- Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. (2013) (357)
- Statistical models and patient predictors of readmission for heart failure: a systematic review. (2008) (352)
- Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis (2012) (338)
- National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. (2014) (330)
- Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. (2015) (326)
- Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. (2014) (322)
- Recent trends in chronic disease, impairment and disability among older adults in the United States (2011) (303)
- Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. (2009) (265)
- Hospital volume and 30-day mortality for three common medical conditions. (2010) (241)
- Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions. (2016) (229)
- Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013 (2016) (224)
- Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study (2011) (221)
- What have we learnt from Vioxx? (2007) (217)
- Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010 (2017) (214)
- The shape of things to come: 3D printing in medicine. (2014) (203)
- National Patterns of Risk-Standardized Mortality and Readmission for Acute Myocardial Infarction and Heart Failure: Update on Publicly Reported Outcomes Measures Based on the 2010 Release (2010) (201)
- Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. (2020) (197)
- Use of health care services by lower-income and higher-income uninsured adults. (2006) (193)
- Effect of blinded peer review on abstract acceptance. (2006) (193)
- Cognitive decline among patients with chronic obstructive pulmonary disease. (2009) (185)
- Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers (2016) (183)
- Cumulative exposure to ionizing radiation from diagnostic and therapeutic cardiac imaging procedures: a population-based analysis. (2010) (175)
- Association of Changing Hospital Readmission Rates With Mortality Rates After Hospital Discharge (2017) (174)
- Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study (2015) (171)
- Use of hospital-based acute care among patients recently discharged from the hospital. (2013) (167)
- Influence of Patients’ Socioeconomic Status on Clinical Management Decisions: A Qualitative Study (2008) (166)
- Regulatory review of novel therapeutics--comparison of three regulatory agencies. (2012) (152)
- Advanced access scheduling outcomes: a systematic review. (2011) (143)
- Comparison of Hospital Risk-Standardized Mortality Rates Calculated by Using In-Hospital and 30-Day Models: An Observational Study With Implications for Hospital Profiling (2012) (143)
- Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence (2019) (142)
- Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study (2016) (122)
- Sharing of clinical trial data among trialists: a cross sectional survey (2012) (117)
- Ushering in a new era of open science through data sharing: the wall must come down. (2013) (115)
- Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis (2013) (113)
- Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes. (2016) (111)
- The ADVANTAGE Seeding Trial: A Review of Internal Documents (2008) (111)
- The Rising Price of Naloxone - Risks to Efforts to Stem Overdose Deaths. (2016) (111)
- Population Of US Practicing Psychiatrists Declined, 2003-13, Which May Help Explain Poor Access To Mental Health Care. (2016) (103)
- Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement. (2021) (100)
- Health care insurance, financial concerns in accessing care, and delays to hospital presentation in acute myocardial infarction. (2010) (97)
- Use of ezetimibe in the United States and Canada. (2008) (97)
- Hospital readmission performance and patterns of readmission: retrospective cohort study of Medicare admissions (2013) (96)
- Electronic Health Record Components and the Quality of Care (2008) (94)
- Reporting of results in ClinicalTrials.gov and high-impact journals. (2014) (93)
- Opioid Prescribing for Opioid‐Naive Patients in Emergency Departments and Other Settings: Characteristics of Prescriptions and Association With Long‐Term Use (2017) (92)
- Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review (2017) (91)
- Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. (2009) (90)
- Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. (2007) (89)
- Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012 (2015) (86)
- Hospital‐Readmission Risk — Isolating Hospital Effects from Patient Effects (2017) (86)
- The importance of clinical trial data sharing: toward more open science. (2012) (86)
- Association of Admission to Veterans Affairs Hospitals vs Non-Veterans Affairs Hospitals With Mortality and Readmission Rates Among Older Men Hospitalized With Acute Myocardial Infarction, Heart Failure, or Pneumonia. (2016) (83)
- Time to publication among completed clinical trials. (2013) (81)
- Quality of care for acute myocardial infarction at urban safety-net hospitals. (2007) (79)
- Physician attitudes toward industry: a view across the specialties. (2010) (78)
- Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011. (2015) (77)
- Development and Use of an Administrative Claims Measure for Profiling Hospital-wide Performance on 30-Day Unplanned Readmission (2014) (76)
- Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study (2018) (75)
- Variation in US Hospital Emergency Department Admission Rates by Clinical Condition (2015) (75)
- Scheduled and unscheduled hospital readmissions among patients with diabetes. (2010) (75)
- Use of fibrates in the United States and Canada. (2011) (75)
- Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials (2018) (74)
- Skilled nursing facility referral and hospital readmission rates after heart failure or myocardial infarction. (2012) (74)
- Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010. (2014) (74)
- Association of Chronic Diseases and Impairments With Disability in Older Adults: A Decade of Change? (2012) (73)
- Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. (2017) (73)
- Promoting transparency in pharmaceutical industry-sponsored research. (2012) (73)
- Adoption of New Glucose-Lowering Medications in the U.S. - the case of SGLT2 inhibitors: Nationwide cohort study. (2019) (72)
- Obstacles to the Adoption of Biosimilars for Chronic Diseases. (2017) (66)
- Accounting For Patients' Socioeconomic Status Does Not Change Hospital Readmission Rates. (2016) (65)
- Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals (2016) (64)
- The cost of breast cancer screening in the Medicare population. (2013) (63)
- Regional variation in cardiac catheterization appropriateness and baseline risk after acute myocardial infarction. (2008) (63)
- A Historic Moment for Open Science: The Yale University Open Data Access Project and Medtronic (2013) (62)
- Beyond insurance coverage: usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey. (2010) (62)
- Evaluation of the Mobile Acute Care of the Elderly (MACE) service. (2013) (61)
- Association of hospital volume with readmission rates: a retrospective cross-sectional study (2015) (60)
- Place of Residence and Outcomes of Patients With Heart Failure: Analysis From the Telemonitoring to Improve Heart Failure Outcomes Trial (2014) (59)
- The cost implications of prostate cancer screening in the Medicare population (2014) (59)
- Prescription-drug coupons--no such thing as a free lunch. (2013) (57)
- US cardiologist workforce from 1995 to 2007: modest growth, lasting geographic maldistribution especially in rural areas. (2011) (57)
- Appropriate proton pump inhibitor use among older adults: a retrospective chart review. (2008) (56)
- Attitudes of hospital leaders toward publicly reported measures of health care quality. (2014) (56)
- Generic atorvastatin and health care costs. (2012) (55)
- Differences in Colonoscopy Quality Among Facilities: Development of a Post-Colonoscopy Risk-Standardized Rate of Unplanned Hospital Visits. (2016) (54)
- Based on key measures, care quality for Medicare enrollees at safety-net and non-safety-net hospitals was almost equal. (2012) (53)
- Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers: Potential Implications for the Choosing Wisely Campaign. (2015) (52)
- Trends and clinical implications of preoperative breast MRI in Medicare beneficiaries with breast cancer (2013) (52)
- Compliance with prospective trial registration guidance remained low in high-impact journals and has implications for primary end point reporting. (2016) (52)
- Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses (2019) (51)
- HbA1c overtesting and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study (2015) (51)
- Overview and experience of the YODA Project with clinical trial data sharing after 5 years (2018) (50)
- Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis (2018) (47)
- Use of recommended ambulatory care services: is the Veterans Affairs quality gap narrowing? (2008) (47)
- Development and Validation of an Algorithm to Identify Planned Readmissions From Claims Data. (2015) (47)
- Adherence to the International Committee of Medical Journal Editors’ (ICMJE) prospective registration policy and implications for outcome integrity: a cross-sectional analysis of trials published in high-impact specialty society journals (2018) (46)
- Use of preventive care by the working poor in the United States. (2007) (46)
- Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation (2016) (44)
- The relationship between systolic blood pressure on admission and mortality in older patients with heart failure (2010) (43)
- Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults (2019) (43)
- Estimating and Reporting on the Quality of Inpatient Stroke Care by Veterans Health Administration Medical Centers (2012) (43)
- A model for dissemination and independent analysis of industry data. (2011) (42)
- Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies (2017) (42)
- Hospital Characteristics Associated With Risk-standardized Readmission Rates (2017) (42)
- Association of the FDA Amendment Act with trial registration, publication, and outcome reporting (2017) (41)
- Gabapentin Approvals, Off-Label Use, and Lessons for Postmarketing Evaluation Efforts. (2018) (41)
- Revisiting Essure--Toward Safe and Effective Sterilization. (2015) (41)
- Study of neurontin: titrate to effect, profile of safety (STEPS) trial: a narrative account of a gabapentin seeding trial. (2011) (40)
- Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices (2019) (40)
- Audit and feedback: an intervention to improve discharge summary completion. (2011) (40)
- Sea change in open science and data sharing: leadership by industry. (2014) (40)
- Pharmaceutical Industry Marketing: Understanding Its Impact on Women’s Health (2008) (40)
- Certificate of Need Regulation and Cardiac Catheterization Appropriateness After Acute Myocardial Infarction (2007) (40)
- Hospital-based, acute care after ambulatory surgery center discharge. (2014) (39)
- Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017 (2020) (39)
- Use of preventive care by elderly male veterans receiving care through the Veterans Health Administration, Medicare fee-for-service, and Medicare HMO plans. (2007) (39)
- Regulatory Review of New Therapeutic Agents - FDA versus EMA, 2011-2015. (2017) (39)
- Association of Racial and Socioeconomic Disparities With Outcomes Among Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, and Pneumonia (2018) (38)
- Trends in readmission rates for safety net hospitals and non-safety net hospitals in the era of the US Hospital Readmission Reduction Program: a retrospective time series analysis using Medicare administrative claims data from 2008 to 2015 (2017) (38)
- Adherence of Pharmaceutical Advertisements in Medical Journals to FDA Guidelines and Content for Safe Prescribing (2011) (38)
- Financial Ties Between Emergency Physicians and Industry: Insights From Open Payments Data. (2016) (38)
- Economic evaluation of a comprehensive teenage pregnancy prevention program: pilot program. (2009) (37)
- Prevalence of Inadequate Blood Pressure Control Among Veterans After Acute Ischemic Stroke Hospitalization: A Retrospective Cohort (2011) (37)
- Availability of Grocery Delivery to Food Deserts in States Participating in the Online Purchase Pilot (2019) (37)
- Patterns and predictors of off-label prescription of psychiatric drugs (2018) (37)
- Poorly Cited Articles in Peer-Reviewed Cardiovascular Journals from 1997 to 2007: Analysis of 5-Year Citation Rates (2015) (37)
- Hospital-based, acute care use among patients within 30 days of discharge after coronary artery bypass surgery. (2013) (37)
- Preventive Care Quality of Medicare Accountable Care Organizations: Associations of Organizational Characteristics With Performance (2016) (36)
- Use of Mechanical Circulatory Support Devices Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock (2021) (36)
- Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study (2020) (36)
- Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011 (2015) (35)
- Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise. (2012) (35)
- Acute Myocardial Infarction and Congestive Heart Failure Outcomes at Specialty Cardiac Hospitals (2007) (35)
- US drug marketing: how does promotion correspond with health value? (2017) (35)
- Rates of Physician Coprescribing of Opioids and Benzodiazepines After the Release of the Centers for Disease Control and Prevention Guidelines in 2016 (2019) (35)
- The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements (2018) (34)
- Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation (2018) (34)
- Time for NIH to lead on data sharing (2020) (33)
- Association Between Insurance Status and Access to Hospital Care in Emergency Department Disposition. (2019) (32)
- Financial Stress and Outcomes after Acute Myocardial Infarction (2012) (32)
- Predictors and outcomes of unplanned readmission to a different hospital. (2015) (32)
- Aggregating multiple real-world data sources using a patient-centered health-data-sharing platform (2020) (31)
- Coronary Artery Bypass Graft: Contemporary Heart Surgery Center Performance in China (2012) (31)
- Regional Density of Cardiologists and Rates of Mortality for Acute Myocardial Infarction and Heart Failure (2013) (31)
- Is P4P really FFS? (2007) (31)
- "Transparency reports" on industry payments to physicians and teaching hospitals. (2012) (31)
- Appropriateness of collaborations between industry and the medical profession: physicians' perceptions. (2009) (31)
- Differences in patient survival after acute myocardial infarction by hospital capability of performing percutaneous coronary intervention: implications for regionalization. (2010) (30)
- Comparative Effectiveness of Generic Atorvastatin and Lipitor® in Patients Hospitalized with an Acute Coronary Syndrome (2016) (30)
- Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection. (2017) (30)
- Assessing the Impact of Screening Colonoscopy on Mortality in the Medicare Population (2011) (30)
- Generic Drug Approvals Since the 1984 Hatch-Waxman Act. (2016) (30)
- What is different about the market for health care? (2007) (29)
- Availability of Investigational Medicines Through the US Food and Drug Administration’s Expanded Access and Compassionate Use Programs (2018) (29)
- Ghostwriting: research misconduct, plagiarism, or fool's gold? (2012) (29)
- The updated AMSA scorecard of conflict-of-interest policies: a survey of U.S. medical schools (2016) (29)
- Dual Use of Veterans Affairs Services and Use of Recommended Ambulatory Care (2008) (29)
- Characterisation of trials where marketing purposes have been influential in study design: a descriptive study (2016) (28)
- The Committee on the Costs of Medical Care and the History of Health Insurance in the United States (2002) (28)
- How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval? (2016) (28)
- Revisiting Essure—Toward Safe and Effective Sterilization (2016) (28)
- Inconsistencies among European Union Pharmaceutical Regulator Safety Communications: A Cross-Country Comparison (2014) (28)
- Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries. (2012) (28)
- Assessment of Preprint Policies of Top-Ranked Clinical Journals (2020) (27)
- Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019. (2021) (27)
- National Prescribing Trends for High‐Risk Anticholinergic Medications in Older Adults (2018) (27)
- Biomedical journal speed and efficiency: a cross-sectional pilot survey of author experiences (2018) (26)
- Submissions and Downloads of Preprints in the First Year of medRxiv. (2020) (26)
- Impact of Hospitalization for Acute Myocardial Infarction on Adherence to Statins Among Older Adults (2016) (26)
- Predictors of clinical trial data sharing: exploratory analysis of a cross-sectional survey (2014) (26)
- Despite Federal Legislation, Shortages Of Drugs Used In Acute Care Settings Remain Persistent And Prolonged. (2016) (25)
- Characterizing expanded access and compassionate use programs for experimental drugs (2017) (25)
- Fulfilling the Mandate of the US Food and Drug Administration's Accelerated Approval Pathway: The Need for Reforms. (2021) (25)
- High incarceration rates among black men enrolled in clinical studies may compromise ability to identify disparities. (2014) (24)
- The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States. (2017) (24)
- Decision-making and cancer screening: a qualitative study of older adults with multiple chronic conditions. (2015) (24)
- EXECUTIVE FUNCTIONING, GROSS MOTOR ABILITY AND MOOD ARE KEY DRIVERS OF POORER QUALITY OF LIFE IN CHILD AND ADOLESCENT SURVIVORS WITH COMPLEX CONGENITAL HEART DISEASE (2011) (24)
- Data sharing through an NIH central database repository: a cross-sectional survey of BioLINCC users (2016) (24)
- Blueprint for Transparency at the U.S. Food and Drug Administration: Recommendations to Advance the Development of Safe and Effective Medical Products (2017) (24)
- Will research preprints improve healthcare for patients? (2018) (23)
- Use of Medicare and Department of Veterans Affairs Health Care by Veterans with Dementia: A Longitudinal Analysis (2009) (23)
- Hospital variation in risk-standardized hospital admission rates from US EDs among adults. (2014) (23)
- Payer-Negotiated Prices in the Diagnosis and Management of Thyroid Cancer in 2021. (2021) (23)
- Loneliness, sadness, and feelings of social disconnection in older adults during the COVID‐19 pandemic (2021) (22)
- Hospital remoteness and thirty-day mortality from three serious conditions. (2008) (22)
- Cardiac Certificate of Need regulations and the availability and use of revascularization services. (2007) (22)
- Evaluation of confounding in epidemiologic studies assessing alcohol consumption on the risk of ischemic heart disease (2019) (21)
- Real-World Evidence: Promise and Peril For Medical Product Evaluation. (2018) (21)
- Age of Data at the Time of Publication of Contemporary Clinical Trials (2018) (21)
- Impact of State Laws That Extend Eligibility for Parents’ Health Insurance Coverage to Young Adults (2012) (21)
- Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study (2018) (21)
- Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010. (2014) (21)
- Use of stroke secondary prevention services: are there disparities in care? (2009) (20)
- A Measure of Care Coordination? (2013) (20)
- Use of Administrative Claims Models to Assess 30-Day Mortality Among Veterans Health Administration Hospitals (2010) (20)
- Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016. (2019) (20)
- Usual Source of Care and Outcomes Following Acute Myocardial Infarction (2014) (20)
- When choosing statin therapy: the case for generics. (2013) (20)
- Determinants of Cardiac Catheterization Use in Older Medicare Patients With Acute Myocardial Infarction (2010) (19)
- Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals (2019) (19)
- Evolution of breast cancer screening in the Medicare population: clinical and economic implications. (2012) (19)
- Publication of pivotal efficacy trials for novel therapeutic agents approved between 2005 and 2011: a cross-sectional study. (2014) (19)
- Availability of Telemedicine Services Across Hospitals in the United States in 2018: A Cross-sectional Study (2020) (19)
- Variation in the Diagnosis of Aspiration Pneumonia and Association with Hospital Pneumonia Outcomes (2018) (19)
- Reporting of noninferiority trials in ClinicalTrials.gov and corresponding publications. (2015) (19)
- Clinical research data sharing: what an open science world means for researchers involved in evidence synthesis (2016) (19)
- A Random Effects Multinomial Logit Analysis of Using Medicare and VA Healthcare Among Veterans With Dementia (2010) (19)
- Open Access Platforms for Sharing Clinical Trial Data. (2016) (19)
- Levothyroxine Use in the United States, 2008-2018. (2021) (19)
- Racial and ethnic differences in personal cervical cancer screening amongst post-graduate physicians: Results from a cross-sectional survey (2008) (19)
- Statewide Inferior Vena Cava Filter Placement, Complications, and Retrievals: Epidemiology and Recent Trends (2018) (19)
- Emergency Department Volume and Outcomes for Patients After Chest Pain Assessment (2018) (19)
- Randomized clinical trials and observational studies are more often alike than unlike. (2014) (18)
- Health and Health Care Use Among Individuals at Risk to Lose Health Insurance With Repeal of the Affordable Care Act (2017) (18)
- Comparison of Hospital Risk-Standardized Mortality Rates using In-hospital and 30-Day Models: Implications for Hospital Profiling (2012) (18)
- Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration. (2020) (18)
- New and incremental FDA black box warnings from 2008 to 2015 (2018) (18)
- Who is missing from the measures? Trends in the proportion and treatment of patients potentially excluded from publicly reported quality measures. (2010) (18)
- Comparison of two independent systematic reviews of trials of recombinant human bone morphogenetic protein-2 (rhBMP-2): the Yale Open Data Access Medtronic Project (2017) (18)
- Declining Admission Rates And Thirty-Day Readmission Rates Positively Associated Even Though Patients Grew Sicker Over Time. (2016) (17)
- Medicare Formulary Coverage Restrictions for Prescription Opioids, 2006 to 2015 (2017) (17)
- Comparative Effectiveness of Generic vs Brand-Name Levothyroxine in Achieving Normal Thyrotropin Levels (2020) (17)
- Age-based and Sex-based Disparities in Screening Colonoscopy Use Among Medicare Beneficiaries (2013) (17)
- Hospital Use of Observation Stays: Cross-sectional Study of the Impact on Readmission Rates (2016) (17)
- Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008-2015. (2019) (17)
- Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries. (2021) (17)
- Modernizing the FDA's 510(k) Pathway. (2019) (17)
- Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada. (2014) (17)
- Description of a research-based health activism curriculum for medical students (2007) (17)
- High Prices for Drugs With Generic Alternatives: The Curious Case of Duexis. (2017) (17)
- Association Between Industry Payments to Physicians and Device Selection in ICD Implantation. (2020) (17)
- Persistence of cardiovascular risk after rofecoxib discontinuation. (2010) (17)
- Affordability and availability of off-patent drugs in the United States—the case for importing from abroad: observational study (2018) (17)
- Transfer rates from nonprocedure hospitals after initial admission and outcomes among elderly patients with acute myocardial infarction. (2014) (16)
- State-sponsored public reporting of hospital quality: results are hard to find and lack uniformity. (2010) (16)
- National trends in stroke after acute myocardial infarction among Medicare patients in the United States: 1999 to 2010. (2015) (16)
- Impact of laboratory cost display on resident attitudes and knowledge about costs (2016) (16)
- Older women with localized breast cancer: costs and survival rates increased across two time periods. (2015) (16)
- Generic Drugs in the United States: Policies to Address Pricing and Competition (2019) (15)
- Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities (2021) (15)
- Laboratory Test Ordering at Physician Offices with and without On-Site Laboratories (2010) (15)
- State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning. (2012) (15)
- Innovation, risk, and patient empowerment: the FDA-mandated withdrawal of 23andMe's Personal Genome Service. (2014) (15)
- Correlation of Inpatient and Outpatient Measures of Stroke Care Quality Within Veterans Health Administration Hospitals (2011) (15)
- Hospital-Based Acute Care After Total Hip and Knee Arthroplasty: Implications for Quality Measurement. (2016) (15)
- Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment (2021) (15)
- Tamiflu: 14 flu seasons and still questions (2013) (14)
- Access to COVID-19 Vaccines in High-, Middle-, and Low-Income Countries Hosting Clinical Trials. (2021) (14)
- Home Health Care After Skilled Nursing Facility Discharge Following Heart Failure Hospitalization (2020) (14)
- Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments (2019) (14)
- Association Between Industry Payments to Physicians and Gabapentinoid Prescribing. (2019) (14)
- Early experience with the FDA’s Breakthrough Devices program (2020) (14)
- Efficacy and safety concerns are important reasons why the FDA requires multiple reviews before approval of new drugs. (2015) (14)
- Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis (2018) (14)
- Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors. (2018) (14)
- Data Desert for Inferior Vena Caval Filters: Limited Evidence, Supervision, and Research. (2017) (14)
- Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure. (2022) (14)
- Accidental drug overdose deaths in Connecticut, 2012-2018: The rise of polysubstance detection? (2019) (14)
- Availability of Clinical Trial Data From Industry‐Sponsored Cardiovascular Trials (2016) (14)
- National assessment of early β-blocker therapy in patients with acute myocardial infarction in China, 2001-2011: The China Patient-centered Evaluative Assessment of Cardiac Events (PEACE)-Retrospective AMI Study. (2015) (14)
- Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA (2020) (14)
- Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines (2017) (14)
- Insurance Coverage and Care of Patients with NonST-Segment Elevation Acute Coronary Syndromes (2007) (14)
- Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics (2021) (14)
- Age‐Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011–2018 (2021) (13)
- Risk-standardized Acute Admission Rates Among Patients With Diabetes and Heart Failure as a Measure of Quality of Accountable Care Organizations: Rationale, Methods, and Early Results (2016) (13)
- Leveraging Open Science to Accelerate Research. (2021) (13)
- Aggregating multiple real-world data sources using a patient-centered health-data-sharing platform. (2019) (13)
- Publication and Dissemination of Results in Clinical Trials of Neurology (2018) (13)
- Health care choices and decisions in the United States and Canada. (2009) (13)
- The Use and Misuse of Thrombolytic Therapy Within the Veterans Health Administration (2012) (13)
- Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs (2021) (13)
- Marketing to physicians in a digital world. (2014) (13)
- Visits for primary care services to primary care and specialty care physicians, 1999 and 2007. (2012) (13)
- Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation (2020) (13)
- Research, regulatory, and clinical decision-making: the importance of scientific integrity. (2018) (12)
- Defining Multiple Chronic Conditions for Quality Measurement (2018) (12)
- Description of a research-based health activism curriculum for medical students (2006) (12)
- Characteristics of available studies and dissemination of research using major clinical data sharing platforms (2021) (12)
- Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study (2018) (12)
- Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study. (2015) (12)
- Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis (2019) (12)
- Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort study (2017) (12)
- Frequency and Importance of Incomplete Screening Fetal Anatomic Sonography in Pregnancy (2016) (12)
- Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS. (2018) (11)
- Identifying Sociodemographic Characteristics Associated With Burden Among Caregivers of the Urban Homebound (2016) (11)
- A Nationwide Assessment of the Association of Smoking Bans and Cigarette Taxes With Hospitalizations for Acute Myocardial Infarction, Heart Failure, and Pneumonia (2016) (11)
- Association of Pharmaceutical Manufacturer Payments to Physicians and Prescribing Dosage of Opioids (2019) (11)
- Early Experiences With Journal Data Sharing Policies: A Survey of Published Clinical Trial Investigators (2018) (11)
- Evaluation of the Anticipated Burden of COVID-19 on Hospital-Based Healthcare Services Across the United States (2020) (11)
- Switching from rosiglitazone: thinking outside the class. (2011) (11)
- Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing (2019) (11)
- Descriptions and interpretations of the ACCORD-Lipid trial in the news and biomedical literature: a cross-sectional analysis. (2014) (11)
- Post‐marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross‐sectional study (2018) (10)
- Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism (2019) (10)
- The US Food and Drug Administration’s expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation (2018) (10)
- On the Need for (Only) High-Quality Clinical Practice Guidelines. (2019) (10)
- US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009–2018 (2020) (10)
- Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug Administration (2021) (10)
- Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis (2019) (10)
- Industry support of physician education in the USA (2016) (10)
- Postmarket Modifications of High-Risk Therapeutic Devices in Otolaryngology Cleared by the US Food and Drug Administration (2015) (10)
- Can machine learning complement traditional medical device surveillance? A case study of dual-chamber implantable cardioverter–defibrillators (2017) (10)
- Risk of Readmission After Discharge From Skilled Nursing Facilities Following Heart Failure Hospitalization: A Retrospective Cohort Study. (2018) (10)
- Association Between Generic-to-Generic Levothyroxine Switching and Thyrotropin Levels Among US Adults. (2022) (10)
- Regulatory watch: Characterizing the US FDA's approach to promoting transformative innovation (2015) (10)
- Impact of Drug Policy on Regional Trends in Ezetimibe Use (2014) (10)
- Reporting Discrepancies Between the ClinicalTrials.gov Results Database and Peer-Reviewed Publications (2014) (10)
- Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study (2017) (10)
- Network Optimization And The Continuity Of Physicians In Medicaid Managed Care. (2018) (10)
- State-Level Population Estimates of Individuals Subject to and Not Meeting Proposed Medicaid Work Requirements (2018) (9)
- The Early Impact of Medicaid Expansion on Uninsured Patients Undergoing Emergency General Surgery. (2018) (9)
- Feasibility of using real-world data in the evaluation of cardiac ablation catheters: a test-case of the National Evaluation System for Health Technology Coordinating Center (2021) (9)
- Data Sharing and Cardiology: Platforms and Possibilities. (2017) (9)
- Feasibility of capturing real-world data from health information technology systems at multiple centers to assess cardiac ablation device outcomes: A fit-for-purpose informatics analysis report (2021) (9)
- Merits of Data Sharing: The Digitalis Investigation Group Trial. (2017) (9)
- Statistical Models and Patient Predictors of Readmission for Heart Failure (2016) (9)
- Renewing the Call for Reforms to Medical Device Safety-The Case of Penumbra. (2021) (9)
- Physician and other healthcare personnel responses to hospital stroke quality of care performance feedback: a qualitative study (2015) (9)
- For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery. (2013) (9)
- Inclusion of Demographic-Specific Information in Studies Supporting US Food & Drug Administration Approval of High-Risk Medical Devices (2017) (9)
- Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval. (2018) (9)
- Patterns of Use of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From 2001 to 2011: China PEACE‐Retrospective AMI Study (2015) (9)
- In Medicaid Managed Care Networks, Care Is Highly Concentrated Among A Small Percentage Of Physicians. (2022) (9)
- U.S. prescribing trends of fentanyl, opioids, and other pain medications in outpatient and emergency department visits from 2006 to 2015. (2019) (9)
- Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines (2018) (9)
- No Time to Wait. (2015) (9)
- Characteristics and Reporting of Number Needed to Treat, Number Needed to Harm, and Absolute Risk Reduction in Controlled Clinical Trials, 2001-2019. (2020) (9)
- Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study (2017) (9)
- Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. (2019) (8)
- Association between physician quality improvement incentives and ambulatory quality measures. (2012) (8)
- The importance of population-based performance measures. (2007) (8)
- Self-Reported and Actual Beta-Blocker Prescribing for Heart Failure Patients: Physician Predictors (2009) (8)
- Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study (2022) (8)
- Insurance coverage and care of patients with non-st-segment elevation acute coronary syndromes. Authors' reply (2007) (8)
- Updated estimates of pharmaceutical company payments to physicians in Vermont. (2008) (8)
- Medicare Prescription Drug Plan Coverage of Hormone Therapies Used by Transgender Individuals. (2020) (8)
- Relationships with the drug industry: More regulation, greater transparency (2009) (8)
- Policy Research: Using Evidence to Improve Healthcare Delivery Systems (2009) (8)
- Post-market clinical research conducted by medical device manufacturers: a cross-sectional survey (2015) (8)
- Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross‐sectional study (2016) (8)
- Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019. (2022) (8)
- Vibration of effects in epidemiologic studies of alcohol consumption and breast cancer risk. (2020) (8)
- Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019 (2021) (8)
- The US Food and Drug Administration 515 Program Initiative: Addressing the Evidence Gap for Widely Used, High-Risk Cardiovascular Devices? (2016) (8)
- Do imaging studies performed in physician offices increase downstream utilization?: an empiric analysis of cardiac stress testing with imaging. (2011) (8)
- Use of Mechanical Cardiopulmonary Resuscitation Devices for Out-of-Hospital Cardiac Arrest, 2010-2016 (2019) (7)
- US Federal Government Efforts to Improve Clinical Trial Transparency with Expanded Trial Registries and Open Data Sharing. (2015) (7)
- Prevalence and significance of race and ethnicity subgroup analyses in Cochrane intervention reviews (2019) (7)
- Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study (2022) (7)
- Sustained Cognitive and Economic Benefits of Resistance Training Among Community- Dwelling Senior Women: A 1-Year Follow-up Study of the Brain Power Study (2010) (7)
- Regulatory Review of New Therapeutic Agents. (2017) (7)
- Comparison of the US and Canadian health care systems: a tale of 2 Mount Sinai's. (2008) (7)
- Age Differences in Hospital Mortality for Acute Myocardial Infarction: Implications for Hospital Profiling (2017) (7)
- Publishing at any cost: a cross-sectional study of the amount that medical researchers spend on open access publishing each year (2021) (7)
- To Expand the Evidence Base About Harms from Tests and Treatments (2021) (7)
- High Costs of FDA Approval for Formerly Unapproved Marketed Drugs. (2017) (7)
- A Measure of Care Coordination? (2012) (7)
- Rate of asthma trial outcomes reporting on ClinicalTrials.gov and in the published literature. (2014) (7)
- Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and Outcomes (2019) (7)
- Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies After Guideline Updates. (2019) (7)
- Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis (2021) (7)
- Direct-to-Consumer Television Advertising: Time to Turn Off the Tube? (2013) (7)
- Clinical Evidence Supporting US Food and Drug Administration Clearance of Novel Therapeutic Devices via the De Novo Pathway Between 2011 and 2019. (2020) (7)
- FDA Policy and Cardiovascular Medicine. (2015) (7)
- Informed Consent and Communicating Risk and Benefits of Research on Higher-Risk Medications. (2015) (7)
- Assessment of Concordance and Discordance Among Clinical Studies Posted as Preprints and Subsequently Published in High-Impact Journals (2021) (6)
- Physician clinical management strategies and reasoning: a cross-sectional survey using clinical vignettes of eight common medical admissions (2014) (6)
- Hospital Discharge and the Transition Home for Poor Patients: “I Knew I Couldn’t Do What They Were Asking Me” (2013) (6)
- Impact of US industry payment disclosure laws on payments to surgeons: a natural experiment (2020) (6)
- Direct-to-consumer personal genomic tests need better regulation (2021) (6)
- Association between FDA black box warnings and Medicare formulary coverage changes. (2017) (6)
- PLACE OF RESIDENCE AND OUTCOMES OF PATIENTS WITH HEART FAILURE: AN ANALYSIS FROM THE TELE-HF TRIAL PARTICIPANTS (2013) (6)
- FDA’s expedited approval programs: evidentiary standards, regulatory trade-offs, and potential improvements (2017) (6)
- Non-Inferiority Designed Cardiovascular Trials in Highest-Impact Journals: Main Findings, Methodological Quality and Time Trends. (2019) (6)
- Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014. (2016) (6)
- Strengthening the FDA's Enforcement of ClinicalTrials.gov Reporting Requirements. (2021) (6)
- Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.gov. (2020) (6)
- US Food and Drug Administration Clearance of Moderate-Risk Otolaryngologic Devices via the 510(k) Process, 1997-2016 (2017) (6)
- On-Label and Off-Label Clinical Studies of FDA-Approved Ophthalmic Therapeutics. (2020) (6)
- Trends in Within-Class Changes in US Average Wholesale Prices for Brand-Name Medications for Common Conditions From 2015 to 2020 (2021) (6)
- Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014 (2017) (6)
- Abstract P46: Correlation Between Inpatient and Outpatient Measures of Stroke Care Quality Within Veterans Health Administration Hospitals (2011) (6)
- Conflicts of interest, authorship, and disclosures in industry-related scientific publications. (2010) (6)
- Confidentiality Orders and Public Interest in Drug and Medical Device Litigation. (2020) (6)
- Mandatory Registration and Results Reporting of Real-World Evidence Studies of FDA-Regulated Medical Products. (2020) (5)
- Accuracy of Computable Phenotyping Approaches for SARS-CoV-2 Infection and COVID-19 Hospitalizations from the Electronic Health Record (2021) (5)
- Bringing Vioxx back to market (2018) (5)
- Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015 (2018) (5)
- Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015 (2020) (5)
- Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011 (2020) (5)
- Strengthening Medical Device Postmarket Safety Surveillance. (2015) (5)
- Restricting interactions with industry to promote evidence-based prescribing. (2014) (5)
- Relationship of Hospital Performance with Readmission and Mortality Rates for Patients Hospitalized with Acute Myocardial Infarction , Heart Failure , or Pneumonia (2013) (5)
- Expanding the frontier of outcomes measurement for public reporting. (2011) (5)
- Individual Patient-Level Data Sharing for Continuous Learning: A Strategy for Trial Data Sharing. (2019) (5)
- Transparency of Regulatory Data across the European Medicines Agency, Health Canada, and US Food and Drug Administration (2021) (5)
- Factors Associated with Refugee Acute Healthcare Utilization in Southern Connecticut (2018) (5)
- National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE)-Retrospective AMI Study, 2001, 2006, and 2011 (2015) (5)
- Why the Open Payments Program Is Likely to Provide Systematic and Transparent Data on Financial Relationships with Industry. (2016) (5)
- Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016 (2018) (5)
- Publishing at any cost: a cross-sectional study of the amount that medical researchers spend on open-access publishing each year (2020) (5)
- Age-treatment subgroup analyses in Cochrane intervention reviews: a meta-epidemiological study (2019) (5)
- Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin (2021) (5)
- On Chlorofluorocarbon Bans and Inhaled Albuterol Prices. (2015) (5)
- Evidence Supporting US Food and Drug Administration Drug Safety Communications. (2019) (5)
- Alirocumab's Price Reduction. (2018) (5)
- Payer-Negotiated Prices for Telemedicine Services (2022) (5)
- Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis (2018) (5)
- Reporting of substance use treatment quality in United States adult drug courts. (2020) (5)
- The Promise of Big Data and Digital Solutions in Building a Cardiovascular Learning System: Opportunities and Barriers. (2020) (5)
- Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis (2018) (5)
- Access to COVID-19 Vaccines in High-, Middle-, and Low-Income Countries Hosting Clinical Trials (2021) (5)
- The Association Between History of Depression and Access to Care Among Medicare Beneficiaries During the COVID-19 Pandemic (2021) (4)
- Characteristics of Retracted Research Articles About COVID-19 vs Other Topics (2022) (4)
- Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval (2021) (4)
- Trial-results reporting and academic medical centers. (2015) (4)
- Patient and provider-level factors associated with changes in utilization of treatments in response to evidence on ineffectiveness or harm (2020) (4)
- Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018 (2021) (4)
- Artificial Intelligence in Breast Cancer Screening: Evaluation of FDA Device Regulation and Future Recommendations. (2022) (4)
- Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance. (2022) (4)
- Physician variation in the de-adoption of ineffective statin and fibrate therapy. (2021) (4)
- Digital medicine systems: an evergreening strategy or an advance in medication management? (2019) (4)
- Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies (2019) (4)
- Medicare's New Device-Coverage Pathway - Breakthrough or Breakdown? (2021) (4)
- Advanced Access Scheduling Outcomes (2017) (4)
- Payments for Acute Myocardial Infarction Episodes-of-Care Initiated at Hospitals With and Without Interventional Capabilities (2014) (4)
- Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics (2019) (4)
- The cost of pharmaceutical innovation to patients (2007) (4)
- Brief report: Housestaff adherence to cervical cancer screening recommendations (2007) (4)
- THE PHYSICAL ACTIVITY CONTRACT—TAILORED TO PROMOTE PHYSICAL ACTIVITY IN A GERIATRIC OUTPATIENT SETTING: A PILOT STUDY (2010) (4)
- Mortality and Readmission at Safety Net and Non-Safety Net Hospitals for Three Common Medical Conditions (2012) (4)
- High-Deductible Health Plans and Higher-Value Decisions: A Mirage or Are We Just Not There Yet? (2016) (4)
- Prioritization of Generic Drug Review-Reply. (2017) (4)
- Clinical Outcomes With Beta-Blocker Use in Patients With Recent History of Myocardial Infarction. (2020) (4)
- Through the looking glass: evaluating the dissemination of research in cardiology. (2012) (4)
- Unplanned hospital visits after ambulatory surgical care (2021) (4)
- Therapeutic Substitution-Should It Be Systematic or Automatic? (2016) (4)
- Hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries (2014) (4)
- USE OF NIACIN IN THE UNITED STATES AND CANADA (2013) (4)
- Discharge disposition disagreements and re-admission risk among older adults: a retrospective cohort study (2012) (4)
- Recent trends in use of inferior vena caval filters in US older adults with acute pulmonary embolism. (2019) (3)
- Exploring Crowdfunding Campaigns for Abortion Services. (2020) (3)
- Identification of Hospitals That Care for a High Proportion of Patients With Social Risk Factors (2021) (3)
- Medicare Formulary Changes After the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline. (2017) (3)
- Mis-SHAPEing Public Health Policy (2009) (3)
- The Philips Respironics Recall of Ventilators and Positive Airway Pressure Machines-Breakdowns in Medical Device Surveillance. (2022) (3)
- Physician Denial of Inappropriate Patient Requests-What If I Say No?? (2018) (3)
- Implementation of 21st Century Cures Act Expanded Access Policies Requirements (2021) (3)
- Abstract 14982: Association Between Industry Payments to Physicians and Device Selection: A Report From the NCDR ICD Registry (2018) (3)
- Abstract 26: Comparison of Medicare Claims with Clinical Trial Outcomes for Follow-up of Older Individuals with Acute Coronary Syndrome (2014) (3)
- Association of Physician Specialty and Medical Therapy for Benign Prostatic Hyperplasia (2014) (3)
- Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021 (2022) (3)
- Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: retrospective cross sectional study (2023) (3)
- EVOLUTION OF THE AMERICAN COLLEGE OF CARDIOLOGY AND THE AMERICAN HEART ASSOCIATION CARDIOLOGY CLINICAL PRACTICE GUIDELINES: A 10-YEAR ASSESSMENT (2019) (3)
- Direct-to-Consumer Television Advertising: Time to Turn Off the Tube? (2013) (3)
- Ensuring correct interpretation of diagnostic test results. (2014) (3)
- Publication of Clinical Studies Supporting FDA Premarket Approval for High-Risk Cardiovascular Devices Between 2011 and 2013: A Cross-sectional Study. (2016) (3)
- Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology. (2022) (3)
- Medicare Beneficiary Out-of-Pocket Costs for Generic Cardiovascular Medications Available Through $4 Generic Drug Discount Programs. (2018) (3)
- Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors (2021) (3)
- Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data (2020) (3)
- Promoting Evidence-Based High-Value Health Care. (2015) (3)
- Deintensification of Routine Medical Services The Next Frontier for Improving Care Quality (2017) (3)
- Weighing the Harms and Benefits of Using Statins for Primary Prevention: Raising the Risk Threshold (2018) (3)
- Clinical Trials-We Get What We Pay For. (2018) (3)
- Response to Letter Regarding Article, “Recent National Trends in Readmission Rates After Heart Failure Hospitalization” (2010) (2)
- Far More Transparency is Needed for COVID-19 Vaccine Trials (2020) (2)
- Use of Recalled Devices in New Device Authorizations Under the US Food and Drug Administration's 510(k) Pathway and Risk of Subsequent Recalls. (2023) (2)
- Impact of left ventricular assist devices and heart transplants on acute myocardial infarction and heart failure mortality and readmission measures (2020) (2)
- Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017 (2018) (2)
- Misreporting of Results of Research in Psychiatry. (2021) (2)
- Accurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population (2018) (2)
- Submissions from the SPRINT Data Analysis Challenge on clinical risk prediction: a cross-sectional evaluation (2019) (2)
- Safety and Effectiveness of a Catheter With Contact Force and 6-Hole Irrigation for Ablation of Persistent Atrial Fibrillation in Routine Clinical Practice (2022) (2)
- THE IMPACT OF CONFLICTS OF INTEREST ON ADJUDICATION AND OUTCOMES IN CARDIOVASCULAR CLINICAL TRIALS (2010) (2)
- 162 EMF Characterizing Hospital-Level Variation in Emergency Department Visitation After Hospital Discharge for Medicare Beneficiaries (2015) (2)
- Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA (2021) (2)
- Global Drug Safety Insights From Taiwan. (2015) (2)
- A multicenter evaluation of computable phenotyping approaches for SARS-CoV-2 infection and COVID-19 hospitalizations (2022) (2)
- Quality of Care in the United States Territories, 1999–2012 (2017) (2)
- Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation (2019) (2)
- Pediatric screening urinalysis: a difference-in-differences analysis of how a 2007 change in guidelines impacted use (2014) (2)
- Access to High-Volume Hospitals for High-Risk Cancer Surgery for Racial and Ethnic Minoritized Groups (2022) (2)
- Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration (2019) (2)
- Evolution of the American College of Cardiology and American Heart Association Cardiology Clinical Practice Guidelines: A 10‐Year Assessment (2019) (2)
- Covid-19, open science, and the CVD-COVID-UK initiative (2021) (2)
- Confronting bias. (2015) (2)
- Would a Breakthrough Therapy by Any Other Name Be as Promising? (2015) (2)
- Withdrawal of Personal Genome Service--reply. (2014) (2)
- Commentary on Bertagnolli et al.: Leveraging electronic health record data for clinical trials—a brave new world (2020) (2)
- Having Their Cake and Eating It Too: Physician Skepticism of the Open Payments Program (2017) (2)
- ANTIHYPERGLYCEMIC MEDICATION PRESCRIBING AND STATE MEDICAID PROGRAM RESPONSES TO ROSIGLITAZONE SAFETY WARNINGS (2012) (2)
- Retracted papers originating from paper mills: cross sectional study (2022) (2)
- Future of covid-19 vaccine pricing: lessons from influenza (2021) (2)
- Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014 (2017) (2)
- Effects of forced disruption in Medicaid managed care on children with asthma. (2021) (2)
- Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017 (2022) (2)
- 38-OR: Differences in Diabetes Medication Use between Commercial and Medicare Advantage Beneficiaries, 2013-2018 (2020) (2)
- Racial disparities in the use of programmed death-1 checkpoint inhibitors. (2017) (2)
- Adoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors. (2017) (2)
- US Food and Drug Administration Approval of Drugs Not Meeting Pivotal Trial Primary End Points, 2018-2021. (2023) (1)
- The Open Translational Science in Schizophrenia (OPTICS) project: an open-science project bringing together Janssen clinical trial and NIMH data (2018) (1)
- Conflicts of Interest Among Authors of Published Cannabidiol Articles, 2014–2019 (2020) (1)
- FIBRINOLYTIC THERAPY IN HOSPITALS WITHOUT PERCUTANEOUS CORONARY INTERVENTION CAPABILITIES IN CHINA FROM 2001 TO 2011 (2014) (1)
- High-risk medical devices: why do we not better understand effectiveness and safety? (2015) (1)
- Abstract 136: The Relationship of Changing Hospital Readmission Rates and Mortality Rates After Hospitalization for Heart Failure, Acute Myocardial Infarction, and Pneumonia (2017) (1)
- NATIONAL MEDICARE FORMULARY COVERAGE AND OUT-OF-POCKET COSTS OF QUADRUPLE THERAPY FOR HEART FAILURE WITH REDUCED EJECTION FRACTION (2022) (1)
- It's not just about the money, money, money…. (2014) (1)
- Moving forward from rhBMP-2: open science and data sharing. (2014) (1)
- Assessment of Health Status and Barriers to Employment Among Medicaid Beneficiaries Not Meeting Work Requirements After Accounting for State Medical Frailty Exemptions. (2020) (1)
- Medicare beneficiaries' plans for the COVID‐19 vaccine in Fall 2020, and why some planned to decline (2021) (1)
- Medicare beneficiaries' out-of-pocket costs for commonly used generic drugs, 2009-2017. (2020) (1)
- Assessment of FDA Approval for New High-risk Therapeutic Devices Not Meeting Pivotal Study Primary End Points, 2016-2020. (2021) (1)
- Adding device identifiers to claims forms—a key step to advance medical device safety (2023) (1)
- Observation encounters and subsequent nursing facility stays. (2015) (1)
- Clinical Evidence Supporting FDA Clearance of First-of-a-Kind Therapeutic Devices via the De Novo Pathway Between 2011 and 2019: A Retrospective Cross-Sectional Analysis (2020) (1)
- Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017 (2019) (1)
- evaluation of a Mobile Acute Care for the Elderly Team for hospitalized older adults: a prospective outcomes study. : b109 (2011) (1)
- Implications of clinical trial data sharing for medical writers (2013) (1)
- The Impact of Off-Patent Drug Acquisitions on Prices (2018) (1)
- Kept in the dark: Scotland rejects “sunshine” legislation (2019) (1)
- Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators (2018) (1)
- Abstract 17159: A Changing Landscape: Contemporary Characteristics of Major Cardiovascular Superiority Trials (2013) (1)
- CUMULATIVE EXPOSURE TO IONIZING RADIATION FROM CARDIAC IMAGING PROCEDURES (2010) (1)
- Abstract 11: Comparative Effectiveness and Safety of Oral Anticoagulants across Baseline Kidney Function (2019) (1)
- Quality of Care in the United States Territories, 1999-2012. (2017) (1)
- Commentary: Diagnostic devices in clinical trials have high stakes for patient care (2016) (1)
- Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation (2021) (1)
- Hospital Discharge and the Transition Home for Poor Patients: “I Knew I Couldn’t Do What They Were Asking Me” (2014) (1)
- PULMONARY EMBOLISM HOSPITALIZATIONS AND USE OF INFERIOR VENA CAVAL FILTERS IN OLDER ADULTS: NATIONAL STUDY OF MEDICARE BENEFICIARIES (2019) (1)
- On Ghosts and Other Unwelcome Guests (2015) (1)
- Making Electronic Health Records Work Better for Patient Care. (2016) (1)
- Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010–2020 (2021) (1)
- Authors’ reply to Ramachandran (2016) (1)
- A Multi-Institutional Review and Validation of Federated Query Results in Multiple Common Data Models (2018) (1)
- Heart Watch Study: protocol for a pragmatic randomised controlled trial (2021) (1)
- MP11-06 REGIONAL-LEVEL INAPPROPRIATE IMAGING RATES FOR PROSTATE AND BREAST CANCERS ARE CORRELATED: POTENTIAL LESSONS FOR THE CHOOSING WISELY CAMPAIGN (2014) (1)
- Catheter-related complications and mortality of atrial fibrillation ablation following introduction of contact force-sensing technology (2020) (1)
- Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings. (2019) (1)
- Optimizing the data available via Health Canada’s clinical information portal (2021) (1)
- Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015. (2017) (1)
- Prevalence, Correlates, and Inter-hospital Variation of Early Outpatient Follow-up After Acute Myocardial Infarction (2010) (1)
- Clinical Trial Evidence for the Real World. (2019) (1)
- Comparison of Serum Cytokine, Chemokine, and Growth Factor Profiles in Crohn's Disease and Food Allergy in Children (2012) (1)
- Differences In Debt Among Postgraduate Medical Residents By Self-Designated Race And Ethnicity, 2014-19. (2023) (1)
- Acute pain pathways: protocol for a prospective cohort study (2021) (1)
- Integrating real-world data to assess cardiac ablation device outcomes in a multicenter study using the OMOP common data model for regulatory decisions: implementation and evaluation (2023) (1)
- Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis (2022) (1)
- Prolonged use of newly prescribed gabapentin after surgery (2022) (1)
- Patterns of Opioid Prescribing among Medicare Advantage Beneficiaries with Pain and Cardiopulmonary Conditions. (2020) (1)
- Comparison of Clinical Study Results Reported in medRxiv Preprints vs Peer-reviewed Journal Articles (2022) (1)
- Spontaneous reporting of post-market safety signals: what evidence should support regulatory action? (2022) (1)
- Consistency between trials presented at conferences, their subsequent publications and press releases (2022) (1)
- On Ghosts and Other Unwelcome Guests (2015) (1)
- A Comparison of Regulatory Approval Time for Ophthalmic Devices in the United States and Japan (2017) (0)
- Impact of left ventricular assist devices and heart transplant on acute myocardial infarction and heart failure mortality and readmission measures (2019) (0)
- Effects of Differences Between Peer Reviewers (2006) (0)
- Abstract acceptance and blinded peer review. Authors' reply (2006) (0)
- Apple Watch and Withings Evaluation of Symptoms, Treatment, and Rhythm in those Undergoing Cardioversion (AWE STRUCk): A Pragmatic Randomized Controlled Trial (2021) (0)
- The Need to Test Strategies Based on Common Sense. (2017) (0)
- Health Affairs Prescribing After Rosiglitazone Warning State Medicaid Programs Did Not Make Use Of Prior Authorization To Promote Safer (2012) (0)
- The OPTICS Project: An Open-Science Framework for the Analysis of Clinical Trial Data (2016) (0)
- 1548-P: Changes in Glucose-Lowering Medication Use in the Era of Cardiovascular Outcomes Trials: Risk/Treatment Paradox Persists (2020) (0)
- State-Sponsored Public Reporting Programs of Hospital Quality in the United States (2011) (0)
- Biomedical journal speed and efficiency: a cross-sectional pilot survey of author experiences (2018) (0)
- Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017. (2020) (0)
- OUTCOMES OF CONTEMPORARY NON-INFERIORITY VERSUS SUPERIORITY CARDIOVASCULAR TRIALS (2021) (0)
- DISSEMINATING EVIDENCE FROM A LANDMARK TRIAL: CROSS-SECTIONAL ANALYSIS OF DESCRIPTIONS AND INTERPRETATIONS OF THE ACCORD-LIPID TRIAL IN THE NEWS AND BIOMEDICAL LITERATURE (2014) (0)
- Abstract 279: Eligibility and Cost Estimates for Anti-inflammatory Therapy for Atherosclerotic Disease: Implications of the CANTOS Trial for the US Adult Population (2018) (0)
- Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017 (2019) (0)
- Gout Treatment in the USA from 2009 to 2016: A Repeated Cross-sectional Analysis (2020) (0)
- Abstract 20158: Long-Term Device-Related Adverse Events After Implantable Cardioverter-Defibrillator Therapy (2014) (0)
- Distribution of Paycheck Protection Program Loans to Healthcare Organizations in 2020 (2021) (0)
- A cross-sectional study (2018) (0)
- Modifications to High-Risk Ophthalmic Devices Following Initial FDA Premarket Approval, 1979-2015 (2017) (0)
- Abstract 17473: Differences in Hospital Risk-standardized Mortality Rates for Acute Myocardial Infarction by Patient Age Group: Implications for Hospital Outcome Profiling (2016) (0)
- The Case for Generic Statins: Not If They Don’t Work So Well—Reply (2013) (0)
- Challenges to Biosimilar Substitution-Reply. (2017) (0)
- PHARMACEUTICAL-INDUSTRY SPONSORED RESEARCH: PROMOTING TRANSPARENCY (2012) (0)
- Off-label Use of Medications-Reply. (2018) (0)
- Early experience with the FDA’s regulatory review of novel gene therapies (2021) (0)
- Abstract 041: Trends in Publication and Methodological Quality of Major Non-inferiority Cardiovascular Trials From 1990-2016: a Systematic Review (2017) (0)
- 2492 Risk of readmission after discharge from skilled nursing facilities following heart failure hospitalization (2018) (0)
- Breakthrough Therapy Designation for New Drugs-Reply. (2018) (0)
- For transparency and accountability more is better (2018) (0)
- Registration, Publication, and Outcome Reporting among Pivotal Clinical Trials that Supported FDA Approval of High-Risk Medical Devices Before and After FDAAA (2021) (0)
- Medical Crowdfunding for Abortion Services [27I] (2020) (0)
- Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020. (2023) (0)
- Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration (2021) (0)
- Coordinating Clinical Trials to Confirm Drug Safety and Efficacy-Resolving Uncertainty. (2019) (0)
- U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016 (2021) (0)
- A MACHINE LEARNING-GUIDED APPROACH FOR ADAPTIVE TRIAL ENRICHMENT AND ACCELERATION OF CARDIOVASCULAR OUTCOME TRIALS: INSIGHTS FROM THE SPRINT AND ACCORD-BP TRIALS (2023) (0)
- ACUTE ADMISSION RATES FOR PATIENTS WITH HEART FAILURE CARED FOR BY ACCOUNTABLE CARE ORGANIZATIONS (2015) (0)
- Reporting Hospital Quality: The Authors Reply (2011) (0)
- Vibration of effects in pooled analyses of Canagliflozin vs placebo, randomized, double blind trials (2020) (0)
- B-45 | Approval, Evidence, and “Off-Label” Device Utilization: The Patent Foramen Ovale Story (2022) (0)
- Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after TREAT trial showed they are ineffective and unsafe (2020) (0)
- Primary care institutional characteristics associated with hypertension awareness, treatment, and control in the China PEACE-Million Persons Project and primary health-care survey: a cross-sectional study. (2023) (0)
- Abstract 14: Regional Cardiologist Density and 30-Day and 1-Year Mortality in Acute Myocardial Infarction and Heart Failure (2013) (0)
- Exploring unique device identifier implementation and use for real-world evidence: a mixed-methods study with NESTcc health system network collaborators (2022) (0)
- Medicare Beneficiary Out-of-Pocket Costs for Generic Cardiovascular Medications Available Through $4 Generic Drug Discount Programs (2018) (0)
- Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial (2021) (0)
- Abstract 11575: Comparative Effectiveness of Generic Atorvastatin and Lipitor® in Patients Hospitalized With an Acute Coronary Syndrome (2015) (0)
- MAJOR CARDIOVASCULAR TRIALS WITH PRIMARY SURROGATE ENDPOINTS: 2006 TO 2011 (2013) (0)
- The Bleeding Edge: Documenting Innovation and Injury in the Medical Device Industry. (2019) (0)
- Medicare's National Coverage Determination for Aducanumab - A One-Off or a Pragmatic Path Forward? (2022) (0)
- Measurement Methodology: What Does Blood Pressure Mean in the PARTAGE Study? (2017) (0)
- Replication Data for: Opioid Prescribing for Opioid-Naive Patients in Emergency Departments and Other Settings: Characteristics of Prescriptions and Association With Long-Term Use (2020) (0)
- We can see the (risks of UV) light. (2015) (0)
- Impact of US industry payment disclosure laws on payments to surgeons: a natural experiment (2020) (0)
- Older drugs with infantile evidence: the illustrative example of loop diuretics. (2018) (0)
- Medical Device User Fee Reauthorization - Back to Basics or Looking Ahead? (2022) (0)
- Abstract 4: The Association Between Admission Rate and 30-Day Risk Standardized Readmission Rate for Heart Failure and Acute Myocardial Infarction (2011) (0)
- Reply: To PMID 23303273. (2013) (0)
- Association of Psychiatric Diagnoses and Medicaid Coverage with Length of Stay Among Inpatients Discharged to Skilled Nursing Facilities (2022) (0)
- Abstract P141: Health Care Insurance, Financial Concerns in Accessing Care, and Nonelective Readmissions Following Acute Myocardial Infarction (2011) (0)
- Clinical studies sponsored by digital health companies participating in the FDA’s Precertification Pilot Program: A cross-sectional analysis (2021) (0)
- A Machine Learning Approach to Post-market Surveillance of Medical Devices (2015) (0)
- SAFETY AND EFFECTIVENESS OF THERMOCOOL ST CATHETER FOR ABLATION OF PERSISTENT ATRIAL FIBRILLATION USING REAL-WORLD DATA (2022) (0)
- Abstract 18805: Association of State Certificate of Need Regulations With the Appropriateness of PCI Procedures (2015) (0)
- Correction of the Framingham Risk Score Data Reported in SPRINT (2017) (0)
- USUAL SOURCE OF CARE AND OUTCOMES AFTER ACUTE MYOCARDIAL INFARCTION: DATA FROM THE PROSPECTIVE REGISTRY EVALUATING MYOCARDIAL INFARCTION: EVENT AND RECOVERY (PREMIER) (2010) (0)
- Making Data Submitted to the Food and Drug Administration More Visible. (2016) (0)
- LINKING THE NCDR CATHPCI REGISTRY WITH ADMINISTRATIVE CLAIMS TO DETERMINE ATTRIBUTION OF REPEAT REVASCULARIZATION FOLLOWING INDEX DRUG-ELUTING STENT IMPLANTATION (2019) (0)
- UNDERREPRESENTATION AND EXCLUSION OF PATIENTS WITH CARDIOVASCULAR DISEASE IN INTENSIVE CARE RANDOMIZED CONTROL TRIALS (2022) (0)
- Upcoding and Anesthesia Risk in Outpatient Gastrointestinal Endoscopy Procedures (2017) (0)
- Additional file 1: of Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis (2019) (0)
- Regional Density Of Cardiologists And Mortality For Acute Myocardial Infarction And Heart Failure (2017) (0)
- Physical activity, patient-reported symptoms, and clinical events: Insights into postprocedural recovery from personal digital devices (2021) (0)
- Perceptions of radiation oncologists and urologists about new technology for the treatment of prostate cancer. (2014) (0)
- The Importance of Independent Evaluation. (2017) (0)
- Clinical Trial Data Sharing: A Cross-Sectional Study of Outcomes Associated with Two NIH Models (2021) (0)
- Abstract 153: Impact Of The Enhance Trial On The Use Of Ezetimibe In The Us And Canada (2013) (0)
- Health Affairs Maldistribution Especially In Rural Areas US Cardiologist Workforce From 1995 To 2007 : Modest Growth , Lasting Geographic (2011) (0)
- Discharged From the Hospital (2013) (0)
- Abstract 216: Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies after Guideline Revisions (2019) (0)
- Abstract P6-07-05: Regional variation in Medicare expenditures for older women with localized breast cancer (2013) (0)
- TRENDS IN THE GEOGRAPHIC DISTRIBUTION OF THE CARDIOVASCULAR WORKFORCE (2011) (0)
- Response to Letter Regarding Article, "Poorly Cited Articles in Peer-Reviewed Cardiovascular Journals from 1997 to 2007: Analysis of 5-Year Citation Rates". (2016) (0)
- Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine use (2021) (0)
- The Human Costs of Medicare Fraud and Abuse. (2019) (0)
- Vibration of effect in more than 16 000 pooled analyses of individual participant data from 12 randomised controlled trials comparing canagliflozin and placebo for type 2 diabetes mellitus: multiverse analysis (2022) (0)
- A SYSTEMATIC REVIEW OF MAJOR NON-INFERIORITY CARDIOVASCULAR TRIALS FROM 2006-2011 (2013) (0)
- Doctors and healthcare reform: a duty to understand? (2014) (0)
- Abstract P255: Should Models of Hospital Outcomes Include Race as a Covariate? (2011) (0)
- Abstract 148: The Timing of 30-Day Readmissions after Hospitalization for Heart Failure and Acute Myocardial Infarction (2012) (0)
- Abstract P41: Predictive Models of Mortality After Stroke: A Systematic Review (2011) (0)
- Unplanned Hospital Admissions after Same-Day Surgery (2016) (0)
- HOSPITAL PERFORMANCE IS NOT ASSOCIATED WITH THE TIMING OR CAUSES OF 30-DAY READMISSION AFTER HOSPITALIZATION FOR HEART FAILURE OR ACUTE MYOCARDIAL INFARCTION (2012) (0)
- Open access to data at Yale University (2018) (0)
- The Supreme Court's Latest Ruling on Drug Liability and its Implications for Future Failure-to-Warn Litigation (2019) (0)
- Hospital Care Efficiency and the SMART (Specific, Measurable, Agreed, Required, and Timely) Medicine Initiative (2017) (0)
- A better pain plan. (2015) (0)
- 8. Syndromic Surveillance System: The Science and Art of Using Big Data to Monitor the Health of New York City (2017) (0)
- Physician Network Connections Associated With Faster De-Adoption of Dronedarone for Permanent Atrial Fibrillation (2021) (0)
- For transparency and accountability more is better (2018) (0)
- Submitted By Yale University/Yale-New Haven Hospital Center for Outcomes Research & Evaluation (YNHH-CORE): (2008) (0)
- Outcomes, Health Policy, and Managed Care Beyond insurance coverage: Usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey (2010) (0)
- Abstract 17512: Differences in Hospital Risk-standardized Mortality Rates for Percutaneous Coronary Intervention by Patient Age Group: Implications for Hospital Outcome Profiling (2016) (0)
- Generating evidence during a pandemic: what’s reliable? (2022) (0)
- Between Heaven and Earth An Introduction to Integrative Approaches to Health Care (0)
- 1157-P: Out-of-Pocket and Health Plan Spending on Diabetes Drugs, 2006-2018 (2020) (0)
- Communicating, and Justifying, Nonefficacy Benefits for New Drugs Approved on the Basis of Noninferiority Trials. (2019) (0)
- Refusal of care by patients. Author's reply (2006) (0)
- Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE (2022) (0)
- S1147 Effect of Gender, Age, and Life Expectancy on Receipt of Screening Colonoscopy in the Medicare Population (2010) (0)
- SAFETY AND EFFECTIVENESS OF THERMOCOOL STSF CATHETER FOR ABLATION OF ISCHEMIC VENTRICULAR TACHYCARDIA (2022) (0)
- Circulation: Cardiovascular Quality and Outcomes (2021) (0)
- Medication Guideline Adherence Among Patients with Markedly Elevated Blood Pressure in A Real-World Setting (2022) (0)
- Patterns of Opioid Prescribing Among Patients with Pain and Cardiopulmonary Conditions (S763) (2020) (0)
- Evidence of publication bias in multiple sclerosis clinical trials: a comparative analysis of published and unpublished studies registered in ClinicalTrials.gov (2023) (0)
- Emulating the GRADE trial using real world data: retrospective comparative effectiveness study (2022) (0)
- Outcomes-Driven Clinical Phenotyping in Cardiogenic Shock using a Mixture of Experts (2021) (0)
- Physician Responses to Apple Watch-Detected Irregular Rhythm Alerts: A Case-Based Survey (2022) (0)
- The YODA Project: Developing Methods for Sharing Clinical Trial Data (2014) (0)
- Pain Management in Older Adults before and during the First Year of Covid-19 Pandemic: Prevalence, Trends, and Correlates. (2023) (0)
- PreScription DigitaL ThErapEutic for Patients with Insomnia (SLEEP-I): a protocol for a pragmatic randomised controlled trial (2022) (0)
- Triage, Copayments, and Emergency Department Visits. (2016) (0)
- Ensuring Public Trust in an Empowered FDA. (2023) (0)
- The Open Translational Science in Schizophrenia (OPTICS) Project: Janssen clinical trial and NIH data together in an Open-Science collaboration (2016) (0)
- Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials (2020) (0)
- Generic competition in a flawed system: pill them, bill them-reply. (2012) (0)
- MONEY LEFT OVER AT THE END OF THE MONTH AND OUTCOMES AFTER MYOCARDIAL INFARCTION (2010) (0)
- Using real-world data from health systems to evaluate the safety and effectiveness of a catheter to treat ischemic ventricular tachycardia (2023) (0)
- Assessment of Market-Level Information on Quality Using Hospital Care Compare (2022) (0)
- Characterizing expanded access and compassionate use programs for experimental drugs (2017) (0)
- Financial conflicts of interest among US physician authors of 2020 clinical practice guidelines: a cross-sectional study (2022) (0)
- Abstract 13: Risks of Death and Hospital Readmission by Time Following Hospitalization for Heart Failure and Acute Myocardial Infarction (2013) (0)
- Implementing clinical trial data sharing requires training a new generation of biomedical researchers (2023) (0)
- Refusal of care by patients. (2006) (0)
- Challenges and solutions to advancing heath equity with medical devices. (2023) (0)
- FDA Indication Extrapolations-Allowing Flexibility While Providing Greater Clarity. (2022) (0)
- Transparency and Accountability of Medicaid Section 1115 Waiver Demonstration Programs Under the Affordable Care Act (2020) (0)
- US Post-Graduate Residency Competitiveness, Trainee Diversity, and Future Salary Among 12 Clinical Specialties (2022) (0)
- Abstract Acceptance and Blinded Peer Review—Reply (2006) (0)
- Analysis of Patient-Focused Information About Left Atrial Appendage Occlusion on US Hospital Web Pages. (2022) (0)
- Abstract 345: Non-inferiority Trials With a Primary Surrogate Endpoint: An Increasing Phenotype in Cardiovascular Trials (2020) (0)
- Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method. (2023) (0)
- Risk After Acute Myocardial Infarction Regional Variation in Cardiac Catheterization Appropriateness and Baseline (2008) (0)
- 180 National Shortages of Drugs Used in the Emergency Department, 2002-2014 (2015) (0)
- HOSPITAL PERCUTANEOUS CORONARY INTERVENTION CAPABILITY IS NOT ASSOCIATED WITH HIGHER PAYMENTS FOR ACUTE MYOCARDIAL INFARCTION PATIENTS (2012) (0)
- NATIONAL PATTERNS OF DIRECT ORAL ANTICOAGULANT PRESCRIBING BY UNITED STATES CLINICIANS AMONG MEDICARE BENEFICIARIES (2021) (0)
- The cost implications of prostate cancer screening in the Medicare population. (2013) (0)
- Characteristics of Novel Therapeutics and Postmarket Safety Events-Reply. (2017) (0)
- Abstract 17838: Discordance Between Findings in Publications and FDA Reviews for New Drug Approvals in Cardiovascular Disease and Diabetes, 2005-2013 (2016) (0)
- Abstract 43: A Case-based Survey Of Physician Practice Patterns Following Asymptomatic, Wearable Device-detected Irregular Rhythm (2022) (0)
- Review of clinical trial settings of drugs commonly used in primary care and approved between 2005 and 2012 (2018) (0)
- Sensible regulation and clinical implementation of clinical decision support software as a medical device (2022) (0)
- FINANCIAL BARRIERS TO CARE AND OUTCOMES AFTER ACUTE MYOCARDIAL INFARCTION: DOES AGE MATTER? (2010) (0)
- Rates of, and factors associated with, switching among generic levothyroxine preparations in commercially insured American adults (2022) (0)
- NON-INFERIORITY TRIALS WITH A PRIMARY SURROGATE ENDPOINT: AN INCREASING PHENOTYPE IN CARDIOVASCULAR TRIALS (2019) (0)
- A Different Case of Penumbra-Reply: A Japanese Framework for Safe and Expedited Access to High-Risk Medical Devices. (2022) (0)
- Abstract 278: High Hospitalization Rates but Steady Improvement in Outcomes of US Older Adults with Pulmonary Embolism (2019) (0)
- Trial evidence and approval of therapeutic agents--reply. (2014) (0)
- Facts Concerning Duexis Prescribing Habits Related to Combination Therapies-Reply. (2017) (0)
This paper list is powered by the following services:
Other Resources About Joseph S. Ross
What Schools Are Affiliated With Joseph S. Ross?
Joseph S. Ross is affiliated with the following schools:
